6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity

Gut

Volumn 39, Issue 3, 1996, Pages 401-406

  Cuffari, C ^a   Theoret Y ^a   Latour, S ^a   Seidman, G ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

6 Mercaptopurine; High performance liquid chromatography; Inflammatory bowel disease; Metabolism

Indexed keywords

MERCAPTOPURINE;

ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CROHN DISEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; ERYTHROCYTE; HEPATITIS; HUMAN; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; REMISSION;

EID: 0029794073     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.3.401     Document Type: Article

References (29)

1. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
2. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intem Med 1995; 122: 132-42.
3. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Büschenfelde KHMZ. Azathioprine combined with prednisolone or monotheraphy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-72.
4. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993; 88: 1198-205.
5. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117: 809-14.
6. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991; 101: 39-46.
7. Perrault J, Greseth JLM, Tremaine WJ. 6-Mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. Mayo Clin Proc 1991; 66: 480-4.
8. Brogan M, Hiserodt J, Olicer M, et al. The effect of 6-mercaptopurine on natural killer cell activities in Crohn's disease. J Clin Immunol 1985; 5: 204-11.
9. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
10. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993; 15: 80-6.
11. Zimm S, Collins JM, Riccardi R, O'Neill R, Narang PK, Chabner B, et al. Variable bioavailability of oral mercaptopunne. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308: 1005-9.
12. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69: 577-9.
13. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyl-transferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54.
14. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
15. Belli D, Seidman EG, Bouthillier L, Weber AM, Roy CC, Plétincx M, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94: 603-10.
16. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. Gastrocnterology 1976; 70: 439-44.
17. Lennard L, Singleton HJ. High-performance liquid Chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chrom Biomed Appl 1994; 661: 25-33.
18. Markowitz J, Daum F. Immunology of inflammatory bowel disease: Summary of the proceedings of the subcommittee on immunosuppressive use in IBD. J Pediatr Gastroenterol Nutr 1991; 12: 411-23.
19. Markowitz J, Grancher K, Mandel F, Mandel F. Immunosuppressive therapy in pediatric inflammatory bowel disease: Results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Am J Gastroenterol 1993; 88: 44-8.
20. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990; 99: 1347-51.
21. Duchesne D, Latours S, Leclerc JM, Sallan SE, Théorêt Y. Pharmacokineties of oral and intravenous 6-Mercaptopurine (6-MP) in childhood acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 1994; 13: A341.
22. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989; 7: 1816-23.
23. Evans WE, Homer M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirements in a thiopurine methyl-transferase deficient child with acute lymphoblastic leukemia. J Pediatr 1991; 119: 985-9.
24. Stet EH, De Abreu RA, Bökkerink JPM, Vogels-Mentink TM, Lambooy LHJ, Trijebls FJM, et al. Reversal of 6-mercaptopurine and 6-methyl-mercaptopurine ribonucleoside cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblasts. Biochem Pharmacol 1993; 46: 547-50.
25. Bökkerink JPM, Stet EH, DeAbreu RA, Damen FJM, Hulscher TW, Bakker MAH, et al. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochcm Pharmacol 1993; 45: 1455-63.
26. Szumlanski C, Weinshilboum RM. Sulphasalazine inhibition of thiopurinemethyltransferase: possible mechanism for interaction with 6-mercaptopurine. Br J Clin Pharmacol 1995; 39: 456-9.
27. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroeterol 1993; 89: 362-6.
28. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1993; 16: 359-63.
29. Cuffari C, Seidman E, Theoret Y. 6-mercaptopurine (6-MP) metabolite measurement in IBD patients' neutrophils correlates with drug efficacy. Gastroenterology 1995; 108: A803.